STEREOTAXIS WKN: A1J09L ISIN: US85916J4094 Kürzel: RJR1 Forum: Aktien Thema: Hauptdiskussion

https://www.stltoday.com/business/local/medical-device-maker-stereotaxis-moving-to-downtown-st-louis-from-cortex/article_2bea54a7-bb5c-510e-ba0f-76069e8ec1ef.html

https://www.youtube.com/watch?v=MNmdSl1_2Yc&t=2585s

https://ir.stereotaxis.com/static-files/5969dce1-c75b-4f17-a3da-cf2195e91648

https://www.bizjournals.com/stlouis/news/2021/02/26/st-louis-surgical-instrument-maker-stereotaxis-mo.html

https://www.smarteranalyst.com/new-blurbs/northland-securities-believes-stereotaxis-stxs-still-has-room-to-grow-2/

https://finance.yahoo.com/news/edited-transcript-stxs-earnings-conference-150000187.html

https://www.stltoday.com/business/columns/david-nicklaus/stereotaxis-ceo-takes-no-salary-but-his-new-stock-award-could-be-worth-many-millions/article_6362aa96-851f-5ba9-ae1b-6a83bbe4f9dc.html

We begin 2021 with purchase orders for five robotic systems reflecting the initial green shoots of a broad-based global resurgence in interest in our robotic technology.” Glaube die wichtigste Info

Stereotaxis EPS beats by $0.01, beats on revenue https://seekingalpha.com/news/3666415-stereotaxis-eps-beats-0_01-beats-on-revenue • Stereotaxis (NYSEMKT:STXS): Q4 GAAP EPS of -$0.02 beats by $0.01. • Revenue of $6.82M (-1.0% Y/Y) beats by $0.79M. • Cash and cash equivalents of $44.2M. • Stereotaxis anticipates robust double-digit revenue growth in 2021, with robotic system revenue of $10-$20M.

Stereotaxis Reports 2020 Full Year Financial Results https://www.globenewswire.com/news-release/2021/02/25/2182568/0/en/Stereotaxis-Reports-2020-Full-Year-Financial-Results.html

https://cardiovascular-webinars.siemens-healthineers-events.com/signup/landing

https://www.globenewswire.com/news-release/2021/02/11/2174187/0/en/Stereotaxis-to-Present-at-Upcoming-Investor-Conferences.html

👍steigt .

https://www.otcmarkets.com/filing/html?id=14488520&guid=YrheUWFqhy2v93h

Stereotaxis (STXS) In a report released today, Jason Wittes from Northland Securities maintained a Buy rating on Stereotaxis, with a price target of $7.00. The company’s shares closed last Monday at $3.99. According to TipRanks.com, Wittes is a 4-star analyst with an average return of 11.6% and a 58.8% success rate. Wittes covers the Healthcare sector, focusing on stocks such as Zimmer Biomet Holdings, Alphatec Holdings, and Globus Medical. Stereotaxis has an analyst consensus of Moderate Buy, with a price target consensus of $7.00. https://www.smarteranalyst.com/new-blurbs/wall-street-analysts-are-bullish-on-top-healthcare-picks-181/